In addition, our study mainly focused on the clinical association between LRRC59 and BC progression and prognosis via the possible regulatory networks, but we are not sure whether LRRC59 regulated BC progression directly through FGF1 or CIP2A pathway. This evidence concerns the gene CIP2A and breast cancer.